Translucence Biosystems presents research at AD/PD™ 2022, Alzheimer's & Parkinson's Diseases Conference

by
Damian Wheeler
March 30, 2022

Dear Collegues,

Translucence Biosystems was honored to present at the AD/PD™ 2022, Alzheimer's & Parkinson's Diseases Conference. Please see our poster presentation entitled, "Brain-Wide Cellular Resolution Measurement of Neuronal Activity, Microglial Activation and β-Amyloid Deposition" below.

Abstract

Recent advances in optical clearing and light sheet imaging have opened an exciting new avenue for brain-wide, cellular resolution immunostaining at the forefront of a dimensional shift from 2D to 3D histology. With access to the intricate anatomy of the whole intact brain, we are developing unbiased and complete pictures of brain pathology for pre-clinical studies.

Methods: With our optimized iDISCO-based clearing methods and our Mesoscale Imaging System for the ZEISS Lightsheet Z.1 microscope, we can image entire mouse brains in ~10 min. Further, our machine learning-enabled 3TK software identifies individual cells or protein aggregates throughout the brain and aligns them to the Allen Reference Atlas to produce a regionalized read-out of patterns across 100’s of brain areas.

Results: We have applied this technology to generate cellular resolution maps of neuronal activity by measuring the immediate-early gene (IEG) products Npas4 and cFos in response to both a light exposure task and in response to contextual fear conditioning. Further, we have optimized methods to identify and count microglia throughout the brain and perform regional analyses of microglial activation.

Importantly, we have used Alzheimer’s Disease model 5xFAD mice to develop assays to generate brain-wide signatures of β-Amyloid deposition. Our automated analysis of microglia and β-Amyloid co-staining allows for brain-wide quantification of plaque-associated microglia. Conclusions: These new methods for whole-brain, next generation 3D immunohistochemistry and anatomics are ideally suited to pre-clinical studies for unbiased, complete and anatomically precise mapping of the efficacy of CNS therapeutics. We thank NIMH for Grants R43MH119989 and R43MH122070.

Ask your question

Send us your questions and we will get back to you as soon as possible
info@translucencebio.com

Thank you! Your submission has been received!
Something went wrong while submitting the form.
Please, contact via us direct email info@translucencebio.comand

Recent news

June 15, 2023

Highlights from the 9th Annual BRAIN Initiative Meeting

Translucence Biosystems recently participated in the 9th Annual BRAIN Initiative Meeting: Open Science, New Tools! The conference, held on June 12-13, 2023, aimed to foster a dynamic and collaborative research community through interactions among like-minded scientists who study the brain.
by
Angela Prvulovic
May 20, 2023

Co-Founder and CEO, Damian Wheeler Presents at KSNeurodegen23 on Brain-Wide Cellular-Resolution Quantification of Microglia and Amyloid

Co-Founder and CEO, Damian Wheeler, presented a poster titled "Brain-Wide Cellular-Resolution Quantification of Microglia and Amyloid" at the Neurodegeneration: New Biology Guiding the Next Generation of Therapeutic Development conference hosted by the by Keystone Symposia on Molecular & Cellular Biology.
by
Angela Prvulovic
March 23, 2023

CEO, Damian Wheeler Ph.D., Presents at the BIO-SEE 2023 Webinar Series

At the BIO-SEE 2023 Webinar Series, Damian Wheeler Ph.D., CEO of Translucence Biosystems, presented the company's innovative approach to brain-wide single-cell imaging in a talk entitled "Brain-wide single-cell resolution imaging and machine learning-enabled quantification".
by
Translucence Biosystems